e-Therapeutics plc (ETX) - Director/PDMR Shareholding RNS Number : 1452R e-Therapeutics plc 14 November 2012 e-Therapeutics plc Director/PDMR Shareholding - Amendment This announcement replaces RNS Number : 7144Q released at 18:01 on 8^th November 2012. e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, announced on 8th November 2012 that Professor Malcolm Young, CEO, had purchased 20,000 shares at 33.5 pence per share for his Self-Invested Personal Pension Fund. Following this purchase, Professor Young's direct beneficial interest increased to 20,640,482 shares (of which 10,310,241 shares are held by Professor Young's wife), representing 14.9% of the total issued share capital of the Company. Professor Young also has an indirect interest, which remained unchanged at 403,148 shares, representing 0.29% of the Company's issued share capital. Professor Young's total interest is therefore 21,043,630 shares. The announcement made on 8 November erroneously stated this number as Professor Young's direct interest and that his indirect holding was additional. -Ends- For more information, please contact: e-Therapeutics plc Malcolm Young / Daniel Elger Tel: +44 (0) 7909 915 068 www.etherapeutics.co.uk Panmure Gordon (UK) Limited Fred Walsh / Hannah Woodley / Grishma Patel Tel: +44 (0) 20 7886 2500 www.panmure.com College Hill Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill Tel: +44 (0) 20 7457 2020 Email: firstname.lastname@example.org CommStrat Group (US) Ted Agne Tel: (+1) 781 631 3117 Email: email@example.com This information is provided by RNS The company news service from the London Stock Exchange END RDSLLFFELALSLIF -0- Nov/14/2012 15:30 GMT
e-Therapeutics plc ETX Director/PDMR Shareholding
Press spacebar to pause and continue. Press esc to stop.